- Home
- CNEY vs AEON Comparison
CNEY vs AEON Comparison
Compare CNEY & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNEY
- AEON
- Stock Information
- Founded
- CNEY 2018
- AEON N/A
- Country
- CNEY China
- AEON United States
- Employees
- CNEY N/A
- AEON N/A
- Industry
- CNEY Major Chemicals
- AEON Biotechnology: Pharmaceutical Preparations
- Sector
- CNEY Industrials
- AEON Health Care
- Exchange
- CNEY Nasdaq
- AEON Nasdaq
- Market Cap
- CNEY 11.3M
- AEON 10.6M
- IPO Year
- CNEY 2021
- AEON N/A
- Fundamental
- Price
- CNEY $1.58
- AEON $0.83
- Analyst Decision
- CNEY
- AEON Strong Buy
- Analyst Count
- CNEY 0
- AEON 1
- Target Price
- CNEY N/A
- AEON $7.20
- AVG Volume (30 Days)
- CNEY 10.9K
- AEON 269.9K
- Earning Date
- CNEY 01-01-0001
- AEON 11-14-2025
- Dividend Yield
- CNEY N/A
- AEON N/A
- EPS Growth
- CNEY N/A
- AEON N/A
- EPS
- CNEY N/A
- AEON N/A
- Revenue
- CNEY $36,049,275.00
- AEON N/A
- Revenue This Year
- CNEY N/A
- AEON N/A
- Revenue Next Year
- CNEY N/A
- AEON N/A
- P/E Ratio
- CNEY N/A
- AEON N/A
- Revenue Growth
- CNEY N/A
- AEON N/A
- 52 Week Low
- CNEY $1.51
- AEON $0.38
- 52 Week High
- CNEY $21.61
- AEON $64.80
- Technical
- Relative Strength Index (RSI)
- CNEY 35.12
- AEON 42.87
- Support Level
- CNEY $1.51
- AEON $0.77
- Resistance Level
- CNEY $1.84
- AEON $1.14
- Average True Range (ATR)
- CNEY 0.07
- AEON 0.11
- MACD
- CNEY -0.00
- AEON -0.01
- Stochastic Oscillator
- CNEY 21.21
- AEON 16.33
About CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.